Abstract 2293
Background
Antacids (AA) are commonly used in the elderly population. Proton pump inhibitors and other drugs to neutralize the gastral pH level and to prevent gastroesophageal reflux are suspected to reduce the efficacy of tyrosine kinase inhibitors. To our knowledge, the effect of AA therapy on SUN efficacy has not been investigated in a real-world mRCC population yet.
Methods
STAR-TOR is a German multicenter registry for pts with mRCC (NCT00700258) which was amended to include SUN pts in June 2010 with regulatory and ethic committee’s approval. Objectives are the evaluation of the safety profile, the tolerability and anti-tumor activity of SUN. Here, we present data on the impact of AA therapy on the therapeutic efficacy of SUN in first-line mRCC pts.
Results
From July 2010 to February 2019, 109 active study sites recruited 550 first line SUN pts. 378 (69%)of these were reported to use AA therapy at baseline, 172 (31%) were AA non-users. Characteristics (AA yes/no): male 66.1/75.1%, median age 67.0/68.0 years, clear cell component: 81.4/81.5%. For all 550 pts, most common drug-related toxicities (incidence ≥ 15%) of any grade were gastrointestinal disorders (38.0%), general disorders including fatigue, mucosal inflammation and edema (29.1%), skin and subcutaneous tissue disorders including hand-foot syndrome (22.7%), nervous system disorders, and blood and lymphatic system disorders (both 19.1%). There was no relevant difference in adverse event rates between AA users and non-users. Efficacy (AA yes vs no): overall response rate 15.1 vs 27.4% (n = 426, p = 0.007), PFS 5.8 vs 8.0 months (mo), p = 0.11; OS 20.3 vs 25.7 mo, p = 0.01.
Conclusions
In our real-world data set, we found a relevant efficacy difference between SUN-treated first-line mRCC pts who used AA therapy at baseline compared with AA non-users, especially in terms of OS. This should be taken into account when prescribing SUN in this setting.
Clinical trial identification
NCT00700258.
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Pharma GmbH, Berlin, Germany.
Funding
Pfizer Pharma GmbH, Berlin, Germany.
Disclosure
K. Schlack: Advisory / Consultancy: Roche, Ipsen, Amgen, Novartis; Travel / Accommodation / Expenses: Bayer, Ipsen, Astellas, Takeda, Pfizer, Sanofi, Janssen-Cilag. M. Boegemann: Honoraria (self): Pfizer, Eisai, MSD, BMS, Ipsen, Eusa Pharma, Novartis. M. Woike: Full / Part-time employment: Pfizer Pharma GmbH. G. Krekeler: Full / Part-time employment: Pfizer Pharma GmbH. T. Fischer: Full / Part-time employment: Winicker-Norimed GmbH. L. Bergmann: Research grant / Funding (institution): BMS; Advisory / Consultancy: BMS, Eusa, Ipsen, Novartis, Pfizer, Roche. M. Rink: Advisory / Consultancy: BMS, Ipsen, MSD, Novartis, Pfizer, Roche. A. Strauss: Advisory / Consultancy: Bayer, MBS, Eisai, Novartis, Pfizer, Roche; Honoraria (self): Amgen, Bayer, BMS, Eisai, Ipsen, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis; Travel / Accommodation / Expenses: Ipsen, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract